Exscientia Ltd.: Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States. Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A
Source: finanznachrichten.de